tbuckley/cabot-search huggingface dataset:
Prolonged Survival of Skin Homograffs in Parous Female Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Edward J. Breyere, Morris K. Barrett
Journal: JNCI Journal of the National Cancer Institute (1960)

The survival of DBA/2 skin homografts was prolonged on postpartum BALB/c female mice parous by DBA/2 males. Survival increased with multiparity through 3 litters, but no additional increase was seen with females that had 4 or more litters. Graft survival was not prolonged on virgins or females parous by intrastrain matings. In this test system, the tolerance induced by parity appeared partial or incomplete because no permanently surviving grafts were observed among 185 test animals. After BALB/c females rejected a homograft of DBA/2 skin, their resistance to a DBA/2 tumor was tested. Normal BALB/c mice can be readily immunized against this tumor by prior inoculation of blood. As expected, the 2 control groups were immunized by the skin and no tumors grew. However, in most of those parous by DBA/2 males some degree of tolerance persisted, as evidenced by growth of the tumor. No indication of maternal immunization by the hybrid fetus was observed.
SOCIETY NEWS.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
Authors: Daniel H. Ahn, Fang-Shu Ou, Bassam Bassam Sonbol, Donald Wender, Kelsey Klute, Zhaohui Jin, Jeremy Clifton Jones, Angela Ulrich, Blake Waechter, Heather Young, Benjamin Adam Weinberg, Heinz-Josef Lenz, John H. Strickler, Tanios S. Bekaii-Saab
Journal: Journal of Clinical Oncology (2022)

TPS213 Background: Regorafenib (R) is an oral multikinase inhibitor that blocks several protein kinases involved in angiogenesis and oncogenesis; it has a survival benefit in refractory metastatic colorectal cancer (mCRC). The current standard (std) treatment in patients (pts) with RAS wildtype (WT) mCRC is sequential treatment with an anti-EGFR antibody (AEA) followed by R. However, R, which is orally administered once daily, may be more convenient and thus preferable for pts than AEA. REVERCE, a Japanese trial, demonstrated a significant 5.8 month (mo.) survival benefit with regorafenib administered prior to AEA compared to the std sequence. Based off these findings, the proposed phase II trial is to confirm the observed survival benefit from regorafenib sequencing prior to anti-EGFR monoclonal antibody therapy in REVERCE in a US patient population. Methods: REVERCEII is an Academic and Community Cancer Research United (ACCRU) network-led randomized phase II study of R (dose escalation from 80mg to 160mg based on tolerance) prior to AEA (R+AEA) compared to standard sequencing (AEA+R) in pts with refractory RAS WT mCRC. Patients are randomized 1:1 to receive R (Arm A) vs. AEA (with or without irinotecan per investigator choice) (Arm B). At the time of disease progression or intolerance, patients will receive sequential treatment until disease progression. Eligibility criteria include histologically confirmed mCRC, ECOG ≤ 2, acceptable organ function, and patients must have had prior fluoropyrimidine, oxaliplatin and irinotecan, and no prior AEA nor R. The primary objective is to compare the overall survival (OS), the primary endpoint, between evaluable patients (eligible, consented, started protocol treatment) who were randomized to R+AEA (arm A) and AEA+R (arm B). With 83 OS events, we have 87% power to detect an improvement in median OS from 9 months to 14.5 mo., assuming 1-sided significance level of 0.15, and exponential distribution. The total sample size is 124 patients. Secondary endpoints include progression-free survival, objective response, and adverse events. The total study duration is expected to be 3 years. Clinical trial information: NCT04117945. Clinical trial information: 04117945.
Interventions for Cutaneous Disease in Systemic Lupus Erythematosus
Authors: Grant Sprow, Mohsen Afarideh, Victoria P. Werth
Journal: JAMA Dermatology (2022)

What is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)?Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.
Bacon: a comprehensive computational benchmarking framework for evaluating targeted chromatin conformation capture-specific methodologies
Authors: Li Tang, Matthew C. Hill, Patrick T. Ellinor, Min Li
Journal: Genome biology (2022)

Chromatin conformation capture (3C)-based technologies have enabled the accurate detection of topological genomic interactions, and the adoption of ChIP techniques to 3C-based protocols makes it possible to identify long-range interactions. To analyze these large and complex datasets, computational methods are undergoing rapid and expansive evolution. Thus, a thorough evaluation of these analytical pipelines is necessary to identify which commonly used algorithms and processing pipelines need to be improved. Here we present a comprehensive benchmark framework, Bacon, to evaluate the performance of several computational methods. Finally, we provide practical recommendations for users working with HiChIP and/or ChIA-PET analyses.
National, State, and Urban Area Vaccination Coverage Among Children Aged 19-35 Months—United States, 2004
Journal: JAMA (2005)

The results of this assessment of the 2004 hurricane season in Florida underscore the need to improve certain areas of hurricane preparedness planning.Approximately half (48.7%) of Floridians had no evacuation plan before any of the hurricanes, including those who resided in counties in the direct path of a hurricane.Efforts should be increased to educate the public regarding the need to evacuate residences not only in the direct paths of hurricanes but also residences away from the direct paths where hazards are posed (e.g., flooding).Survey results also indicated that portable generators were used for electric power in an estimated 17.5% of occupied Florida residences.Among persons using generators, 4.6% reported operating them improperly inside a home or garage.Surveillance data from this period identified 56 reported carbon monoxide-exposure incidents, resulting in treatment of 167 persons and six deaths. 6During the 2004 hurricane season, FDOH periodically released notices regarding the dangers of carbon monoxide poisoning, especially involving the use of portable generators.Public education regarding the proper use of generators and the dangers of carbon monoxide should be increased to reduce the risk for exposures throughout the hurricane season.The findings in this report are subject to at least five limitations.First, the sample size of 1,706 was too small for strata analyses, particularly regarding difficulties faced by adults with chronic conditions and treatment sought by those reporting emotional or mental health conditions.Second, the response rate for the survey was 42.5%.Third, the sample design for the Florida BRFSS did not provide county-level data to assess local impact of the four hurricanes.However, other reports have addressed local impact of specific 2004 hurricanes and the needs of target populations, such as older adults. 7-9 Fourth, BRFSS does not reach residents who are temporarily or permanently without a land-line telephone, and interviews by cellular telephone are
<i>Index of Four Hundred and Fifty-eight Post-Mortems of the Insane. Number 1187-1638</i>. State Hospital for the Insane, Norristown, Pa. Charles J. Swalm, M. D., Pathologist, and Abraham L. Mann, M. D.,Assistant Pathologist. With an Introduction by Allen J. Smith, A. M.,M. D., etc., Consulting Pathologist of the Hospital. (<i>Norristown, Pa.: Published by Authority of the Board of Trustees, 1915</i>.)
Journal: American Journal of Psychiatry (1916)
Coping and-immunosuppression: Inescapable but not escapable shock suppresses lympfrocyte proliferation Landenslager ML, Ryan SM, Drugan RC, Hyson RL, Maier SF: Science 221:568, 1983
Authors: Harold Friedman, Ohio Monroe, Coleman Stamford, Walzer Bridgeport, Berger Freehold, N Bert, Kahn Tyler, David Stein Suffern
Journal: Journal of Allergy and Clinical Immunology (1984)
Maladies allergiques
Authors: Max Samter
Journal: JAMA (1964)

<i>Maladies allergiques</i>is long overdue: the foreword states correctly that a French textbook on allergic diseases does not exist. The fact is surprising if one considers the discoveries and technical advances which French scientists have contributed to the discipline. The treatise is uneven. The fundamental sections are readable and informative, but applied immunology changes so rapidly that a book which has required years of preparation cannot be uniformly up to date: the loose-leaf binding which permits periodic revision is an attractive attempt to solve this predicament. The clinical sections suggest that the editors have been restrained and, at times, too gentle: the chapters emphasize the preferences and preoccupations of their authors. The sections on treatment are less convincing, less critical than the preceding sections. They represent a curious mixture of accepted and abandoned approaches to therapy without sufficient attempt to place them in proper perspective. While the format of the
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets
Authors: Zhangfeng Zhong, Chi Teng Vong, Feiyu Chen, Horyue Tan, Cheng Zhang, Ning Wang, Liao Cui, Yitao Wang, Yibin Feng
Journal: Medicinal Research Reviews (2022)

Abstract Immunotherapy sheds new light to cancer treatment and is satisfied by cancer patients. However, immunotoxicity, single‐source antibodies, and single‐targeting stratege are potential challenges to the success of cancer immunotherapy. A huge number of promising lead compounds for cancer treatment are of natural origin from herbal medicines. The application of natural products from herbal medicines that have immunomodulatory properties could alter the landscape of immunotherapy drastically. The present study summarizes current medication for cancer immunotherapy and discusses the potential chemicals from herbal medicines as immune checkpoint inhibitors that have a broad range of immunomodulatory effects. Therefore, this review provides valuable insights into the efficacy and mechanism of actions of cancer immunotherapies, including natural products and combined treatment with immune checkpoint inhibitors, which could confer an improved clinical outcome for cancer treatment.
Gilteritinib clinical activity in relapsed/refractory <scp><i>FLT3</i></scp> mutated <scp>acute myeloid leukemia</scp> previously treated with <scp><i>FLT3</i></scp> inhibitors
Authors: Yazan Numan, Zaid Abdel Rahman, Justin Grenet, Stephanie Boisclair, Jan Philipp Bewersdorf, Cailin Collins, Dylan Barth, Martina Fraga, Dale L. Bixby, Amer M. Zeidan, Musa Yilmaz, Pankil Desai, Gabriel Mannis, Yehuda E. Deutsch, Yasmin Abaza, Shira Dinner, Olga Frankfurt, Mark Litzow, Aref Al‐Kali, James M. Foran, Lisa Z. Sproat, Borko Jovanovic, Naval Daver, Alexander E. Perl, Jessica K. Altman
Journal: American Journal of Hematology (2022)

Abstract Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3‐mutation ( FLT3 mut+ ). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3 mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CR i + CR with incomplete platelet recovery [CRp]) was 48.7% ( n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen‐activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value &lt;.01.
Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells
Authors: Martin J Lett, Hema Mehta, Adrian Keogh, Tina Jaeger, Maxime Jacquet, Kate Powell, Marie-Anne Meier, Isabel Fofana, Hassan Melhem, Jürg Vosbeck, Gieri Cathomas, Andres Heigl, Markus H Heim, Emanuel Burri, Kirsten D Mertz, Jan Hendrik Niess, Otto Kollmar, Christoph J Zech, Robert Ivanek, Urs Duthaler, Paul Klenerman, Deborah Stroka, Magdalena Filipowicz Sinnreich
Journal: Gut (2022)

Mucosal-associated invariant T (MAIT) cells are the most abundant T cells in human liver. They respond to bacterial metabolites presented by major histocompatibility complex-like molecule MR1. MAIT cells exert regulatory and antimicrobial functions and are implicated in liver fibrogenesis. It is not well understood which liver cells function as antigen (Ag)-presenting cells for MAIT cells, and under which conditions stimulatory Ags reach the circulation.We used different types of primary human liver cells in Ag-presentation assays to blood-derived and liver-derived MAIT cells. We assessed MAIT cell stimulatory potential of serum from healthy subjects and patients with portal hypertension undergoing transjugular intrahepatic portosystemic shunt stent, and patients with inflammatory bowel disease (IBD).MAIT cells were dispersed throughout healthy human liver and all tested liver cell types stimulated MAIT cells, hepatocytes being most efficient. MAIT cell activation by liver cells occurred in response to bacterial lysate and pure Ag, and was prevented by non-activating MR1 ligands. Serum derived from peripheral and portal blood, and from patients with IBD stimulated MAIT cells in MR1-dependent manner.Our findings reveal previously unrecognised roles of liver cells in Ag metabolism and activation of MAIT cells, repression of which creates an opportunity to design antifibrotic therapies. The presence of MAIT cell stimulatory Ags in serum rationalises the observed activated MAIT cell phenotype in liver. Increased serum levels of gut-derived MAIT cell stimulatory ligands in patients with impaired intestinal barrier function indicate that intrahepatic Ag-presentation may represent an important step in the development of liver disease.
Complete left bundle-branch block (LBBB) is associated with increased 1-year mortality in patients with congestive heart failure (CHF): Data from IN-CHF registry Samuele Baldasseroni, Cristina Opasich, Marco Gorini, Niccol� Marchionni, Carlo Campana, Antonella Deorsola, Giulio Masotti, Luigi Tavazzi, Aldo P. Maggioni. ANMCO Research Center, Florence, Italy, Dept. of Critical Care Medicine and Surgery Section of Geriatric Medicine, University of Florence, Florence, Italy
Journal: Journal of the American College of Cardiology (2001)
Endoscopy International Open – recently published
Journal: Endoscopy (2020)

Comment on:Digital per-oral cholangioscopy to diagnose and manage biliary duct disorders: a single-center retrospective studyEndosc Int Open 2020; 08(06): E796-E804DOI: 10.1055/a-1153-8950Comment on:Nodularity-like appearance in the cardia: novel endoscopic findings for Helicobacter pylori infectionEndosc Int Open 2020; 08(06): E770-E774DOI: 10.1055/a-1136-9890Comment on:Use of washing cytology from removed self-expandable metal stents for biliary strictures: a novel cytology methodEndosc Int Open 2020; 08(06): E748-E752DOI: 10.1055/a-1144-2668
Computer-Aided Detection Does Not Improve Mammogram Accuracy
Journal: JNCI Journal of the National Cancer Institute (2011)

Using computer-aided detection (CAD) software to help analyze and interpret mammograms does not improve accuracy, according to a study published online July 27 in the Journal of the National Cancer Institute.CAD software, used currently for analyzing three out of four mammograms in the United States, identifies patterns associated with breast cancers and marks potential abnormalities for the radiologist to consider before making a final recommendation.To learn whether CAD leads to more accurate reading of mammograms, Joshua J. Fenton, M.D., at the University of California, Davis, and colleagues analyzed data from more than 1.6 million film screening mammograms carried out at facilities in seven states from 1998 to 2006.The facilities participate in the Breast Cancer Surveillance Consortium, a federally supported network in which data quality is rigorously monitored.Of 90 total facilities, 25 adopted CAD and used it for an average of 27.5 months during the study period.The researchers collected information on women who had mammograms with and without CAD, including whether they were diagnosed with breast cancer within a year of the screening.According to the study, CAD was associated with more false positives-identifications of tumors that turned out to be false.It did not improve detection of invasive cancers.Moreover, the cancers detected using CAD were no more likely to be smaller or at a lower stage or to have less lymph node involvement than those detected without CAD.The results were the same after adjusting for patient age, breast density, use of hormone replacement therapy, and other factors that might influence mammography findings.
Treatment of Familial Benign Chronic Pemphigus With Superficial Radiotherapy
Authors: Hans Christian Wulf, Stine Regin Wiegell
Journal: JAMA Dermatology (2022)

Hailey-Hailey disease (HHD) is a chronic genodermatosis with recurrent vesicles and erosions mainly in the intertriginous areas. Hailey-Hailey disease severely affects patient quality of life. Standard treatments attempt to control the flares, but often do not result in long-term remission of the disease.To describe outcomes of treatment with superficial radiotherapy (SR) for severe treatment-refractory HHD.This retrospective case-series included 13 patients with severe HHD with a mean (SD) duration of 24 (14) years whose treatments with SR and follow-up were conducted at the Department of Dermatology at Bispebjerg University Hospital (Copenhagen, Denmark) from January 2015 to April 2021.Patients were treated with SR (20 kilovolt; 8 fractions of 2 gray was equal to 1 cycle) with a total dose of 16 gray in each treatment cycle. Patients received 1 to 6 treatment cycles with 1 to 5 separate body areas treated in each cycle. Sixty-two separate body areas were treated with SR.Complete long-term remission, defined as no relapse during follow-up of at least 12 months.For the 13 participants (mean [SD] age, 52 [18] years; 8 women [62%]), 56 of 62 treated areas (90%) achieved long-term remission, and the mean (SD) follow-up was 32 (12) months for the successfully treated areas. Nine of 13 patients (69%) responded with complete remission of all treated areas after the first treatment cycle and an additional 3 patients experienced complete remission after the second SR cycle. One patient with partial remission in 1 of 2 treated skin areas experienced such an improvement in HHD that they chose to abstain from retreatment. The treatment was followed by severe inflammation lasting for up to 1 month followed by temporary slight hyperpigmentation of the treated areas. The average Dermatology Life Quality Index score before treatment with SR was 22 (the disease having extremely large effect on the patient's life) and decreased to an average of 3 (small effect on the patient's life) after treatment with SR.The results of this case series suggest that treatment with SR was associated with remission in patients with severe HHD and may provide a long-term improvement of treated skin areas.
Covid-19: Many hospitals “are not declaring critical incidents” despite severe pressures
Authors: Ingrid Torjesen
Journal: BMJ (2022)

Covid-19: Many hospitals "are not declaring critical incidents" despite severe pressures Ingrid TorjesenThe number of official critical incidents declared by NHS hospital trusts is likely to massively underestimate the real severity of the situation in NHS acute care, a senior leader has told The BMJ.